DFP-13318

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug NameDFP-13318
Drug Alias NamePolyethylene-glycol-SN 38-conjugatesPEG-SN-38 conjugatesPegylated SN-38 conjugate PLX038Pegylated SN-38 PLX038PLX-038 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursFallopian Tube NeoplasmsSmall Cell Lung Carcinoma +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesProlynx Llc
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesInstitut CurieProlynx Llc
Active IndicationsFallopian Tube NeoplasmsSmall Cell Lung CarcinomaOvarian Neoplasms +[9] 
Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A